Skip to main content

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study

Enrolling by invitation · Phase 3 · NCT05967351

Conditions: Duchenne Muscular Dystrophy

At a glance

Research payments reported, 2025
$1.3M
U.S. investigators named
24
Sites paid
32
Planned or actual enrollment
400

About the trial

Sponsor
Sarepta Therapeutics, Inc. (with Hoffmann-La Roche)
Tested
delandistrogene moxeparvovec (genetic)
Dates
Started 2023-09-27; completion 2033-10-31
Results posted
Not yet

The purpose of this study is to provide a single clinical study with a uniform approach to monitoring long-term safety and efficacy in participants who received delandistrogene moxeparvovec in a previous clinical study. No study drug will be administered as part of this study.

From ClinicalTrials.gov, last updated 2026-02-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Sarepta Therapeutics, Inc. reported $1.3M in research payments for this study in 2025 (1,046 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.